We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

Mereo BioPharma

Raring to go in rare diseases

Initiation | 24 September 2018


Core business continues to deliver, as CARMA enters the clinic

Lighthouse | 24 September 2018


E-FIT stroke trial results disappoint

Update | 04 September 2018

Tissue Regenix

Executing the plan

Update | 03 September 2018


Q218 results highlight progress made in the period

Lighthouse | 23 August 2018


The defining inflection point expected within three weeks

Update | 17 August 2018


First NBT system delivered in US for Major Depression indication

Lighthouse | 16 August 2018


Transitioning with growing confidence

Update | 30 July 2018

Tissue Regenix

Creating the right conditions for future growth

Initiation | 23 July 2018


Good CARMA: IND milestone achieved

Update | 16 July 2018
1 2 3 4 5 6 7 8 9 10 11
110 results found.